Badry Bursulaya

This inventor holds 17 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Irm LLC, Novartis Ag. Active years: 2006-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Badry Bursulaya. Retrieved from https://idiyas.com/inventor/badry-bursulaya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 8)

% Patents Active = 29.4

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 7.5

ph-index = 2

Forward Citations = 38(Granted Patents)

Location History:

San Diego, CA (US) (2006 - 2012)
Escondito, CA (US) (2017)
Escondido, CA (US) (2013 - 2021)

Company Filing History:

Years Active: 2006-2021

Loading Chart...

Areas of Expertise:

Aza-Indazole Compounds

Tendon Injuries

Ligament Injuries

EGFR Activity

Kinase Inhibitors

Protease Inhibitors

Pyrrolidones

Anti-HIV Activity

Cathepsin S Inhibitors

Oxindoles

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11203595 - Aza-indazole compounds for use in tendon and/or ligament injuries (2021-12-21),

2. 10766894 - Aza-indazole compounds for use in tendon and/or ligament injuries (2020-09-08),

3. 10112907 - Substituted indazoles for treating tendon and/or ligament injuries (2018-10-30),

4. 9585970 - Site-specific labeling methods and molecules produced thereby (2017-03-07),

5. 9440957 - Compounds and compositions for modulating EGFR Activity (2016-09-13),

6. 8440681 - 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors (2013-05-14),

7. 8338469 - Compounds and compositions as channel activating protease inhibitors (2012-12-25),

8. 8178526 - Compounds and compositions as ITPKb inhibitors (2012-05-15),

9. 7951823 - Compounds and compositions as channel activating protease inhibitors (2011-05-31),

10. 7939547 - Compounds and compositions as channel activating protease inhibitors (2011-05-10),

11. 7601742 - Pyrrolidones with anti-HIV activity (2009-10-13),

12. 7501408 - Inhibitors of cathepsin S (2009-03-10),

13. 7495016 - Pyrrolidones with anti-HIV activity (2009-02-24),

14. 7384970 - Inhibitors of cathepsin S (2008-06-10),

15. 7314872 - Inhibitors of cathepsin S (2008-01-01),

Title: Badry Bursulaya: Innovator in Tendon and Ligament Injury Solutions

Introduction

Badry Bursulaya is an accomplished inventor based in San Diego, California. With a remarkable portfolio of 17 patents to his name, he has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative solutions for tendon and ligament injuries.

Latest Patents

Among his latest inventions is a groundbreaking patent involving Aza-indazole compounds designed for use in tendon and/or ligament injuries. This invention provides a compound of formula (I) in its free form or in a pharmaceutically acceptable salt form, alongside a method for manufacturing these compounds. Additionally, it includes therapeutic uses as well as a combination of pharmacologically active agents and a pharmaceutical composition, showcasing Bursulaya's commitment to advancing medical treatments.

Career Highlights

Throughout his career, Badry Bursulaya has worked with notable companies, including Irm LLC and Novartis AG. His experience in these influential organizations has enriched his expertise and fueled his passion for innovation in the pharmaceutical industry.

Collaborations

Bursulaya's work has brought him alongside talented professionals in the field, including coworkers David C. Tully and Arnab Kumar Chatterjee. These collaborations have undoubtedly played a pivotal role in the development of his patents and innovations.

Conclusion

In conclusion, Badry Bursulaya stands out as a prominent inventor in the realm of tendon and ligament injury solutions. His inventions reflect a deep understanding of pharmaceuticals and an innovative spirit dedicated to improving patient outcomes. With his continued research and development, he is poised to make even greater contributions to the medical field in the future.

Profile summary based on public USPTO records.